Cargando…

A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases

Fibrosis is the result of chronic inflammation and is known to pathologically occur in many organs and systems. Pirfenidone (PFD) is an anti-fibrotic known for its use in idiopathic pulmonary fibrosis (IPF). In addition to being an anti-fibrotic, it acts as an anti-inflammatory and antioxidant as we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, Parth V, Balani, Prachi, Lopez, Angel R, Nobleza, Chelsea Mae N, Siddiqui, Mariah, Khan, Safeera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861090/ https://www.ncbi.nlm.nih.gov/pubmed/33564498 http://dx.doi.org/10.7759/cureus.12482

Ejemplares similares

Comparing the Efficacy, Safety, and Superiority of Calcitonin Gene-Related Peptide Monoclonal Antibodies and Botox in Preventing and Treating Migraines
por: Siddiqui, Mariah, et al.
Publicado: (2021)

The Relationship of Rapid Eye Movement Sleep Behavior Disorder and Freezing of Gait in Parkinson’s Disease
por: Nobleza, Chelsea Mae N, et al.
Publicado: (2020)

Correction: Comparing the Efficacy, Safety, and Superiority of Calcitonin Gene-Related Peptide Monoclonal Antibodies and Botox in Preventing and Treating Migraines
por: Siddiqui, Mariah, et al.
Publicado: (2021)

Can Pioglitazone Safeguard Patients of Lichen Planus Against Homocysteine Induced Accelerated Cardiovascular Aging and Reduced Myocardial Performance: A Systematic Review
por: Balani, Prachi, et al.
Publicado: (2020)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis With Pirfenidone and Nintedanib: A Friend or Foe
por: Kaushal, Mohit, et al.
Publicado: (2022)

Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)

The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent
Publicado: (2013)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
por: Takeda, Yoshito, et al.
Publicado: (2014)

Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients
por: Feng, Haoshen, et al.
Publicado: (2020)

Survival and lung function decline in patients with definite, probable and possible idiopathic pulmonary fibrosis treated with pirfenidone
por: Májek, Ondřej, et al.
Publicado: (2022)

Role and New Insights of Pirfenidone in Fibrotic Diseases
por: Lopez-de la Mora, David Alejandro, et al.
Publicado: (2015)

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2017)

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1
por: Xi, Yue, et al.
Publicado: (2021)

Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis
por: Bracco Gartner, Thomas C. L., et al.
Publicado: (2022)

Effectiveness and Safety of Pirfenidone and Nintedanib for Pulmonary Fibrosis in COVID-19-Induced Severe Pneumonia: An Interventional Study
por: Choudhary, Rajkamal, et al.
Publicado: (2022)

Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience
por: Alhamad, Esam H.
Publicado: (2015)

Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results
por: Salih, Goran Nadir, et al.
Publicado: (2016)

Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis
por: Ren, Hui, et al.
Publicado: (2017)

Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use
por: Lyseng-Williamson, Katherine A.
Publicado: (2017)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
por: Costabel, Ulrich, et al.
Publicado: (2019)

Pirfenidone-Induced Photosensitivity in a Patient with Idiopathic Pulmonary Fibrosis
por: Kim, Ho-Jin, et al.
Publicado: (2018)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017)

Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone
por: Kubbara, Aahd, et al.
Publicado: (2023)

Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts
por: Zhou, Chaoming, et al.
Publicado: (2016)

The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC
por: Marwitz, Sebastian, et al.
Publicado: (2020)

Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
por: Aravena, Carlos, et al.
Publicado: (2015)

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
por: Lehtonen, Siri T., et al.
Publicado: (2016)

Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
por: Tzouvelekis, Argyrios, et al.
Publicado: (2017)

Correction to: Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
por: Belhassen, Manon, et al.
Publicado: (2021)

Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review
por: Amati, Francesco, et al.
Publicado: (2023)

Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro
por: Wei, Qilu, et al.
Publicado: (2021)

Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models
por: Yu, Wencheng, et al.
Publicado: (2016)

Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients
por: Huang, Hui, et al.
Publicado: (2015)

Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases?
por: Dhooria, Sahajal, et al.
Publicado: (2015)

Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
por: Valeyre, Dominique, et al.
Publicado: (2014)

Correction: Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
por: Aravena, Carlos, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6e4hshq4lcrvla89o7icah5etv